KR102160841B1 - 2-피리돈 화합물 - Google Patents

2-피리돈 화합물 Download PDF

Info

Publication number
KR102160841B1
KR102160841B1 KR1020157012117A KR20157012117A KR102160841B1 KR 102160841 B1 KR102160841 B1 KR 102160841B1 KR 1020157012117 A KR1020157012117 A KR 1020157012117A KR 20157012117 A KR20157012117 A KR 20157012117A KR 102160841 B1 KR102160841 B1 KR 102160841B1
Authority
KR
South Korea
Prior art keywords
compound
cyclopropyl
present
phenyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157012117A
Other languages
English (en)
Korean (ko)
Other versions
KR20150082301A (ko
Inventor
쇼이치 구로다
유다이 이마이
다카노리 가와구치
게이코 후세기
마사히로 보노
하지메 아사누마
도모미치 쵸난
나가아키 사토
쇼이치 몬마
시게타다 사사코
마리에 미즈타니
신 이토
다쿠미 오카다
히로후미 오타
세이시 이시야마
Original Assignee
닛산 가가쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 닛산 가가쿠 가부시키가이샤 filed Critical 닛산 가가쿠 가부시키가이샤
Publication of KR20150082301A publication Critical patent/KR20150082301A/ko
Application granted granted Critical
Publication of KR102160841B1 publication Critical patent/KR102160841B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
KR1020157012117A 2012-11-13 2013-11-12 2-피리돈 화합물 Expired - Fee Related KR102160841B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012249792 2012-11-13
JPJP-P-2012-249792 2012-11-13
PCT/JP2013/080517 WO2014077235A1 (ja) 2012-11-13 2013-11-12 ２－ピリドン化合物

Publications (2)

Publication Number Publication Date
KR20150082301A KR20150082301A (ko) 2015-07-15
KR102160841B1 true KR102160841B1 (ko) 2020-09-28

Family

ID=50731146

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157012117A Expired - Fee Related KR102160841B1 (ko) 2012-11-13 2013-11-12 2-피리돈 화합물

Country Status (25)

Country Link
US (1) US9695148B2 (enExample)
EP (1) EP2921489B1 (enExample)
JP (1) JP5963025B2 (enExample)
KR (1) KR102160841B1 (enExample)
CN (1) CN104768944B (enExample)
AU (1) AU2013345930B2 (enExample)
BR (1) BR112015010823A2 (enExample)
CA (1) CA2891406C (enExample)
DK (1) DK2921489T3 (enExample)
ES (1) ES2641469T3 (enExample)
HU (1) HUE034557T2 (enExample)
IL (1) IL238701B (enExample)
IN (1) IN2015DN03869A (enExample)
MX (1) MX361479B (enExample)
MY (1) MY173812A (enExample)
NO (1) NO2921489T3 (enExample)
NZ (1) NZ707832A (enExample)
PH (1) PH12015501056A1 (enExample)
PL (1) PL2921489T3 (enExample)
PT (1) PT2921489T (enExample)
RU (1) RU2662157C2 (enExample)
SG (1) SG11201503716RA (enExample)
TW (1) TWI591064B (enExample)
WO (1) WO2014077235A1 (enExample)
ZA (1) ZA201503323B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6048533B2 (ja) * 2014-05-12 2016-12-21 日産化学工業株式会社 ２−ピリドン化合物を含有する医薬
EP3144305A4 (en) * 2014-05-13 2017-12-27 Nissan Chemical Industries, Ltd. Method for producing 2-pyridone compound
JP7265276B2 (ja) * 2018-05-31 2023-04-26 華領医薬技術（上海）有限公司 グルコキナーゼ活性化剤およびｓｇｌｔ－２阻害薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275069A (en) 1979-01-22 1981-06-23 The Upjohn Company Anti-diabetic 1,2-dihydro-2-oxo-6-alkyl-nicotinic acids
SI1169312T1 (en) 1999-03-29 2005-02-28 F. Hoffmann-La Roche Ag Glucokinase activators
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
CN101466691B (zh) 2006-06-08 2011-07-27 伊莱利利公司 作为组ⅰ代谢型受体拮抗剂的取代的甲酰胺类化合物
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
US7928230B2 (en) * 2007-07-17 2011-04-19 Bristol-Myers Squibb Company Method for modulating GPR119 G protein-coupled receptor and selected compounds
EP2318370A1 (en) 2008-07-29 2011-05-11 Pfizer Inc. Fluorinated heteroaryls
SG181123A1 (en) 2009-12-04 2012-07-30 Taisho Pharmaceutical Co Ltd 2-pyridone compounds
JP2013010750A (ja) * 2011-06-02 2013-01-17 Taisho Pharmaceutical Co Ltd ２−ピリドン化合物を含有する医薬

Also Published As

Publication number Publication date
AU2013345930A1 (en) 2015-06-04
SG11201503716RA (en) 2015-06-29
JPWO2014077235A1 (ja) 2017-01-05
EP2921489B1 (en) 2017-09-06
CN104768944B (zh) 2017-03-29
WO2014077235A1 (ja) 2014-05-22
PL2921489T3 (pl) 2018-01-31
CA2891406C (en) 2021-03-16
TWI591064B (zh) 2017-07-11
BR112015010823A2 (pt) 2017-07-11
EP2921489A1 (en) 2015-09-23
IN2015DN03869A (enExample) 2015-10-02
MX2015005884A (es) 2015-12-09
AU2013345930B2 (en) 2017-08-24
RU2015122717A (ru) 2017-01-10
CA2891406A1 (en) 2014-05-22
PH12015501056B1 (en) 2015-07-27
EP2921489A4 (en) 2016-04-06
TW201434826A (zh) 2014-09-16
ES2641469T3 (es) 2017-11-10
ZA201503323B (en) 2016-08-31
JP5963025B2 (ja) 2016-08-03
US20160289208A1 (en) 2016-10-06
RU2662157C2 (ru) 2018-07-24
PH12015501056A1 (en) 2015-07-27
IL238701A0 (en) 2015-06-30
NZ707832A (en) 2019-03-29
US9695148B2 (en) 2017-07-04
MY173812A (en) 2020-02-24
DK2921489T3 (en) 2017-10-16
HK1207856A1 (en) 2016-02-12
NO2921489T3 (enExample) 2018-02-03
KR20150082301A (ko) 2015-07-15
MX361479B (es) 2018-12-06
CN104768944A (zh) 2015-07-08
HUE034557T2 (en) 2018-02-28
IL238701B (en) 2018-10-31
PT2921489T (pt) 2017-12-01

Similar Documents

Publication Publication Date Title
JP6204975B2 (ja) Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体
US20250074897A1 (en) Pyridazinones as parp7 inhibitors
AU2009331179B2 (en) Novel bicyclic heterocyclic compound
US9242977B2 (en) Trk-inhibiting compound
CN103153963B (zh) 环丙烷化合物
KR20160134865A (ko) 아미드 유도체 및 이의 약제학적으로 허용되는 염, 이의 제조방법 및 이의 의학적 적용
TW201400486A (zh) 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒□衍生物
JP2009535357A (ja) １１−β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤
US20240400518A1 (en) Sos1 inhibitor and use thereof
CN103402995B (zh) 吲哚、吲唑衍生物或其盐
EA024939B1 (ru) 1h-индазол-3-карбоксамидные соединения в качестве ингибиторов гликогенсинтазы киназы 3-бета
TWI829481B (zh) 雙環吲唑糖皮質素受體拮抗劑
KR102160841B1 (ko) 2-피리돈 화합물
TW202515867A (zh) 17β-羥基類固醇脫氫酶13型之抑制劑及其使用方法
JP6048533B2 (ja) ２−ピリドン化合物を含有する医薬
KR20240014050A (ko) Pd1/pd-l1 억제제로서의 화합물 및 이의 방법
TW201625588A (zh) 環狀胺衍生物
HK1207856B (en) 2-pyridone compound
KR20230118695A (ko) 아데노신 a2a 수용체 길항제 및 이의 용도
WO2017215586A1 (zh) 酰胺类衍生物、其制备方法及其在医药上的用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230923

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230923